181 related articles for article (PubMed ID: 33132262)
1. [Pharmacological properties and clinical efficacy of dotinurad (URECE
Taniguchi T; Ashizawa N
Nihon Yakurigaku Zasshi; 2020; 155(6):426-434. PubMed ID: 33132262
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
3. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Ishikawa T; Takahashi T; Taniguchi T; Hosoya T
Expert Opin Pharmacother; 2021 Aug; 22(11):1397-1406. PubMed ID: 33926357
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
5. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):44-52. PubMed ID: 31754882
[TBL] [Abstract][Full Text] [Related]
7. Stronger Uricosuric Effects of the Novel Selective URAT1 Inhibitor UR-1102 Lowered Plasma Urate in Tufted Capuchin Monkeys to a Greater Extent than Benzbromarone.
Ahn SO; Ohtomo S; Kiyokawa J; Nakagawa T; Yamane M; Lee KJ; Kim KH; Kim BH; Tanaka J; Kawabe Y; Horiba N
J Pharmacol Exp Ther; 2016 Apr; 357(1):157-66. PubMed ID: 26907620
[TBL] [Abstract][Full Text] [Related]
8. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):62-70. PubMed ID: 31980978
[TBL] [Abstract][Full Text] [Related]
9. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout.
Hosoya T; Fushimi M; Okui D; Sasaki T; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):80-91. PubMed ID: 31875931
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
[TBL] [Abstract][Full Text] [Related]
11. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout.
Hosoya T; Furuno K; Kanda S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):71-79. PubMed ID: 31970593
[TBL] [Abstract][Full Text] [Related]
12. A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients.
Hosoya T; Furuno K; Kanda S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):103-111. PubMed ID: 32067130
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of a novel selective urate reabsorption inhibitor "dotinurad" among patient groups with different stages of renal dysfunction.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Nephrol; 2021 Dec; 25(12):1336-1345. PubMed ID: 34328574
[TBL] [Abstract][Full Text] [Related]
14. Uric acid-lowering effect of dotinurad, a novel selective urate reabsorption inhibitor, in hypertensive patients with gout or asymptomatic hyperuricemia: a pooled analysis of individual participant data in phase II and III trials.
Takahashi T; Beppu T; Hidaka Y; Hosoya T
Clin Exp Hypertens; 2021 Nov; 43(8):730-741. PubMed ID: 34425059
[No Abstract] [Full Text] [Related]
15. Comparative efficacy and safety of uricosuric agents in the treatment of gout or hyperuricemia: a systematic review and network meta-analysis.
Li YJ; Chen LR; Yang ZL; Wang P; Jiang FF; Guo Y; Qian K; Yang M; Yin SJ; He GH
Clin Rheumatol; 2023 Jan; 42(1):215-224. PubMed ID: 36036279
[TBL] [Abstract][Full Text] [Related]
16. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment.
Kumagai Y; Sakaki M; Furihata K; Ito T; Inoue K; Yoshida T; Matsumoto S; Furuno K; Hagino A
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):25-35. PubMed ID: 31760530
[TBL] [Abstract][Full Text] [Related]
17. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
Omura K; Miyata K; Kobashi S; Ito A; Fushimi M; Uda J; Sasaki T; Iwanaga T; Ohashi T
Drug Metab Pharmacokinet; 2020 Jun; 35(3):313-320. PubMed ID: 32327267
[TBL] [Abstract][Full Text] [Related]
18. Uricosuric Agents Affect Plasma and Kidney Concentration of Adefovir via Inhibition of Oat1 and Mrp2 in Rats.
Motoki K; Taniguchi T; Ashizawa N; Sakai M; Chikamatsu N; Yamano K; Iwanaga T
Biol Pharm Bull; 2023; 46(2):170-176. PubMed ID: 36724945
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of the Uricosuric Effect of Dotinurad by
Fujita K; Zhu Q; Arakawa H; Shirasaka Y; Tamai I
Drug Metab Dispos; 2023 Nov; 51(11):1527-1535. PubMed ID: 37643882
[TBL] [Abstract][Full Text] [Related]
20. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA).
Tanaka A; Taguchi I; Hisauchi I; Yoshida H; Shimabukuro M; Hongo H; Ishikawa T; Kadokami T; Yagi S; Sata M; Node K;
Eur J Med Res; 2023 Jul; 28(1):238. PubMed ID: 37461063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
